BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruiting now · Phase 1
Conditions studied: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
In brief
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Key facts
- Study ID
- NCT06917079
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- People needed
- 665
- Starts
- 2025-03-31
- Expected to finish
- 2029-09-01
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
- Measurable disease by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- Life expectancy >24 weeks
- Adequate organ function
You may not qualify if…
- Malignancy within the last 2 years as specified in the protocol
- Untreated brain metastases
- Other inclusion/exclusion criteria are specified in the protocol.
Where it is running
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California, United States (enrolling)
- University of California Davis — Sacramento, California, United States (enrolling)
- University of California San Diego Moores Cancer Center — San Diego, California, United States (enrolling)
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (enrolling)
- Yale University — New Haven, Connecticut, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- OSF Healthcare Cancer Institute — Peoria, Illinois, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- NYU Langone Health — New York, New York, United States (enrolling)
- Columbia University Irving Medical Center — New York, New York, United States (enrolling)
- Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)
- Sarah Cannon Research Institute at Mary Crowley — Dallas, Texas, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- NEXT Oncology — San Antonio, Texas, United States (enrolling)
- Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.